Clinical Trial Update: The Safety and Efficacy of ZVS106e in the Treatment of IRDs Caused by Biallelic Mutations in ABCA4 [EARLY_Phase 1]

View source ↗

Summary

Early-phase Phase 1 trial evaluating the safety and efficacy of ZVS106e for Stargardt disease caused by biallelic ABCA4 mutations; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stargardt Disease

Drugs mentioned

• ZVS106e

Snippet

Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University | Conditions: Stargardt | EARLY_Phase 1 | Status: RECRUITING